Webinar

Heart Failure (HF) is a relentlessly progressive disease state previously manageable only by guideline directed medical therapy (GDMT). While this approach has been proven to reduce HF morbidity and mortality, there continue to be issues with compliance, and new medications are often sub optimally utilized. This lecture will review current GDMT recommendations and discuss late breaking pharmaceutical options. Novel breakthrough CCM® therapy for NYHA Class III patients with normal sinus rhythm and an EF between 45% and 25% who are not indicated for CRT will be discussed as a way to close the treatment gap between GDMT and CRT that has existed for too long. It has been more than two decades since a new device-based option has emerged for patients with no other alternatives. This will be your chance to become familiar with patient identification techniques you can use to find appropriate candidates for CCM® therapy in your practice.